Mikael Dolsten Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mikael Dolsten.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mikael Dolsten. Mikael Dolsten is Sr. VP & Pres., Wyeth Research in WYETH ($WYE) and President R&D in PFIZER INC ($PFE) and Director in Karyopharm Therapeutics Inc. ($KPTI).
Latest Insider Trading Transactions of Mikael Dolsten
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, KPTI, PFE, WYE
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 21 2021 | KPTI | Karyopharm Therape ... | Dolsten Mikael | Director | Option Exercise | A | 9.42 | 23,900 | 225,138 | 23,900 | |
Mar 01 2021 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 33.82 | 182,050 | 6,156,931 | 182,050 | |
Mar 01 2021 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 33.82 | 210,697 | 7,125,773 | 210,697 | |
Mar 01 2021 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 33.82 | 28,271 | 956,125 | 156,568 | 184.8 K to 156.6 K (-15.29 %) |
May 19 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 37.79 | 24,242 | 916,105 | 174,918 | 199.2 K to 174.9 K (-12.17 %) |
May 19 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 37.78 | 17,357 | 655,747 | 199,160 | 216.5 K to 199.2 K (-8.02 %) |
May 19 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 37.80 | 16,840 | 636,552 | 216,517 | 233.4 K to 216.5 K (-7.22 %) |
May 19 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 37.77 | 14,727 | 556,239 | 233,357 | 248.1 K to 233.4 K (-5.94 %) |
May 19 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 37.75 | 9,700 | 366,175 | 248,084 | 257.8 K to 248.1 K (-3.76 %) |
May 19 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 37.81 | 6,470 | 244,631 | 257,784 | 264.3 K to 257.8 K (-2.45 %) |
May 19 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 37.76 | 5,517 | 208,322 | 264,254 | 269.8 K to 264.3 K (-2.05 %) |
May 19 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 37.82 | 500 | 18,910 | 269,771 | 270.3 K to 269.8 K (-0.18 %) |
Mar 03 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 33.42 | 39,446 | 1,318,285 | 268,515 | 308 K to 268.5 K (-12.81 %) |
Feb 28 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 34.10 | 182,461 | 6,221,920 | 182,461 | |
Feb 28 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 34.10 | 212,961 | 7,261,970 | 212,961 | |
Feb 28 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 34.72 | 22,314 | 774,742 | 307,961 | 330.3 K to 308 K (-6.76 %) |
Feb 28 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 34.72 | 15,478 | 537,396 | 330,275 | 345.8 K to 330.3 K (-4.48 %) |
Feb 28 2020 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Grant | A | 0.00 | 45,566 | 0 | 345,753 | 300.2 K to 345.8 K (+15.18 %) |
Jun 07 2019 | KPTI | Karyopharm Therape ... | Dolsten Mikael | Director | Option Exercise | A | 5.43 | 25,000 | 135,750 | 25,000 | |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 32.23 | 126,366 | 4,072,776 | 0 | |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 30.59 | 155,172 | 4,746,711 | 0 | |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.52 | 38,645 | 1,681,830 | 289,126 | 327.8 K to 289.1 K (-11.79 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.53 | 3,250 | 141,473 | 327,771 | 331 K to 327.8 K (-0.98 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.54 | 2,600 | 113,204 | 331,021 | 333.6 K to 331 K (-0.78 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.55 | 2,400 | 104,520 | 333,621 | 336 K to 333.6 K (-0.71 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.56 | 2,187 | 95,266 | 336,021 | 338.2 K to 336 K (-0.65 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.56 | 77,484 | 3,375,203 | 338,208 | 415.7 K to 338.2 K (-18.64 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.57 | 14,760 | 643,093 | 415,692 | 430.5 K to 415.7 K (-3.43 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.58 | 5,927 | 258,299 | 430,452 | 436.4 K to 430.5 K (-1.36 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 43.59 | 2,300 | 100,257 | 436,379 | 438.7 K to 436.4 K (-0.52 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 32.23 | 48,582 | 1,565,798 | 438,679 | 390.1 K to 438.7 K (+12.45 %) |
Mar 05 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 30.59 | 57,609 | 1,762,259 | 390,097 | 332.5 K to 390.1 K (+17.33 %) |
Mar 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 43.35 | 126,762 | 5,495,133 | 126,762 | |
Mar 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 43.35 | 150,419 | 6,520,664 | 150,419 | |
Mar 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 42.93 | 47,101 | 2,022,046 | 332,488 | 379.6 K to 332.5 K (-12.41 %) |
Mar 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 42.93 | 26,672 | 1,145,029 | 379,589 | 406.3 K to 379.6 K (-6.57 %) |
Mar 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Grant | A | 0.00 | 96,183 | 0 | 406,261 | 310.1 K to 406.3 K (+31.02 %) |
Feb 26 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 42.96 | 54,568 | 2,344,241 | 310,078 | 364.6 K to 310.1 K (-14.96 %) |
Feb 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 27.37 | 164,534 | 4,503,296 | 0 | |
Feb 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 34.59 | 144,928 | 5,013,060 | 0 | |
Feb 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 34.59 | 42,061 | 1,454,890 | 362,051 | 320 K to 362.1 K (+13.14 %) |
Feb 01 2019 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 27.37 | 83,907 | 2,296,535 | 319,990 | 236.1 K to 320 K (+35.54 %) |
Sep 17 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 32.23 | 158,662 | 5,113,676 | 0 | |
Sep 17 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 21.03 | 185,185 | 3,894,441 | 0 | |
Sep 17 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 32.23 | 57,211 | 1,843,911 | 234,299 | 177.1 K to 234.3 K (+32.31 %) |
Sep 17 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 21.03 | 124,501 | 2,618,256 | 177,088 | 52.6 K to 177.1 K (+236.75 %) |
Aug 14 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | I | 0.00 | 24,504 | 0 | 100,677 | |
Jun 20 2018 | KPTI | Karyopharm Therape ... | Dolsten Mikael | Director | Option Exercise | A | 18.80 | 17,000 | 319,600 | 17,000 | |
Mar 12 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 36.61 | 32,457 | 1,188,251 | 51,185 | 83.6 K to 51.2 K (-38.80 %) |
Mar 12 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 36.56 | 15,459 | 565,181 | 83,642 | 99.1 K to 83.6 K (-15.60 %) |
Mar 12 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 36.60 | 9,900 | 362,340 | 99,101 | 109 K to 99.1 K (-9.08 %) |
Mar 12 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 36.59 | 5,300 | 193,927 | 109,001 | 114.3 K to 109 K (-4.64 %) |
Mar 12 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 36.57 | 4,154 | 151,912 | 114,301 | 118.5 K to 114.3 K (-3.51 %) |
Mar 12 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 36.55 | 2,329 | 85,125 | 118,455 | 120.8 K to 118.5 K (-1.93 %) |
Mar 12 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 36.58 | 100 | 3,658 | 120,784 | 120.9 K to 120.8 K (-0.08 %) |
Mar 05 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 35.85 | 13,986 | 501,398 | 120,884 | 134.9 K to 120.9 K (-10.37 %) |
Mar 02 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 27.37 | 198,238 | 5,425,774 | 0 | |
Mar 02 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 35.70 | 120,330 | 4,295,781 | 134,870 | 255.2 K to 134.9 K (-47.15 %) |
Mar 02 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 36.31 | 38,152 | 1,385,299 | 255,200 | 293.4 K to 255.2 K (-13.01 %) |
Mar 02 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 27.37 | 198,238 | 5,425,774 | 293,352 | 95.1 K to 293.4 K (+208.42 %) |
Feb 27 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 18.90 | 174,081 | 3,290,131 | 0 | |
Feb 27 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | I | 0.00 | 16,547 | 0 | 123,093 | |
Feb 27 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 35.98 | 55,544 | 1,998,473 | 115,772 | 171.3 K to 115.8 K (-32.42 %) |
Feb 27 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 36.26 | 53,949 | 1,956,191 | 171,316 | 225.3 K to 171.3 K (-23.95 %) |
Feb 27 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 18.90 | 174,081 | 3,290,131 | 225,265 | 51.2 K to 225.3 K (+340.11 %) |
Feb 23 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 35.74 | 120,792 | 4,317,106 | 120,792 | |
Feb 23 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 35.74 | 120,792 | 4,317,106 | 120,792 | |
Feb 23 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 35.74 | 144,485 | 5,163,894 | 144,485 | |
Feb 23 2018 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 35.74 | 144,485 | 5,163,894 | 144,485 | |
Jun 19 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | I | 0.00 | 16,682 | 0 | 135,956 | |
Jun 16 2017 | KPTI | Karyopharm Therape ... | Dolsten Mikael | Director | Option Exercise | A | 9.18 | 17,000 | 156,060 | 17,000 | |
Mar 03 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.55 | 15,401 | 532,105 | 49,318 | 64.7 K to 49.3 K (-23.80 %) |
Mar 03 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.48 | 15,569 | 536,819 | 64,719 | 80.3 K to 64.7 K (-19.39 %) |
Mar 01 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.26 | 27,523 | 942,938 | 80,288 | 107.8 K to 80.3 K (-25.53 %) |
Mar 01 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.27 | 24,668 | 845,372 | 107,811 | 132.5 K to 107.8 K (-18.62 %) |
Mar 01 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 34.28 | 16,581 | 568,397 | 132,479 | 149.1 K to 132.5 K (-11.12 %) |
Mar 01 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 34.28 | 16,400 | 562,192 | 149,060 | 165.5 K to 149.1 K (-9.91 %) |
Mar 01 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.25 | 6,655 | 227,934 | 165,460 | 172.1 K to 165.5 K (-3.87 %) |
Mar 01 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Grant | A | 0.00 | 31,800 | 0 | 172,115 | 140.3 K to 172.1 K (+22.66 %) |
Feb 27 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 34.06 | 121,294 | 4,131,274 | 121,294 | |
Feb 27 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 34.06 | 146,104 | 4,976,302 | 146,104 | |
Feb 27 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 21.03 | 218,447 | 4,593,940 | 0 | |
Feb 27 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 32.49 | 105,761 | 3,436,175 | 140,315 | 246.1 K to 140.3 K (-42.98 %) |
Feb 27 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 34.06 | 53,839 | 1,833,756 | 246,076 | 299.9 K to 246.1 K (-17.95 %) |
Feb 27 2017 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 21.03 | 218,447 | 4,593,940 | 299,915 | 81.5 K to 299.9 K (+268.14 %) |
Nov 16 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | I | 0.00 | 149,747 | 0 | 149,747 | |
Jun 17 2016 | KPTI | Karyopharm Therape ... | Dolsten Mikael | Director | Option Exercise | A | 8.06 | 10,000 | 80,600 | 10,000 | |
May 05 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 33.45 | 28,435 | 951,151 | 370,619 | 399.1 K to 370.6 K (-7.13 %) |
May 05 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 33.47 | 15,000 | 502,050 | 399,054 | 414.1 K to 399.1 K (-3.62 %) |
May 05 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 33.46 | 14,000 | 468,440 | 414,054 | 428.1 K to 414.1 K (-3.27 %) |
May 05 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 33.48 | 9,900 | 331,452 | 428,054 | 438 K to 428.1 K (-2.26 %) |
May 05 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 33.48 | 153 | 5,122 | 437,954 | 438.1 K to 438 K (-0.03 %) |
May 05 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 33.49 | 100 | 3,349 | 438,107 | 438.2 K to 438.1 K (-0.02 %) |
Mar 01 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 30.23 | 9,549 | 288,666 | 435,210 | 444.8 K to 435.2 K (-2.15 %) |
Mar 01 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Grant | A | 0.00 | 18,530 | 0 | 444,759 | 426.2 K to 444.8 K (+4.35 %) |
Feb 26 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 30.59 | 138,675 | 4,242,068 | 138,675 | |
Feb 26 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 30.59 | 155,172 | 4,746,711 | 155,172 | |
Feb 26 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 18.90 | 210,280 | 3,974,292 | 0 | |
Feb 26 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 29.67 | 99,223 | 2,943,946 | 426,229 | 525.5 K to 426.2 K (-18.88 %) |
Feb 26 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 30.02 | 52,450 | 1,574,549 | 525,452 | 577.9 K to 525.5 K (-9.08 %) |
Feb 26 2016 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 18.90 | 210,280 | 3,974,292 | 577,902 | 367.6 K to 577.9 K (+57.20 %) |
May 26 2015 | KPTI | Karyopharm Therape ... | Dolsten Mikael | Director | Option Exercise | A | 26.15 | 10,000 | 261,500 | 10,000 | |
Apr 02 2015 | KPTI | Karyopharm Therape ... | Dolsten Mikael | Director | Option Exercise | A | 30.61 | 20,000 | 612,200 | 20,000 | |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.48 | 30,700 | 1,058,536 | 355,911 | 386.6 K to 355.9 K (-7.94 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.47 | 7,939 | 273,657 | 386,611 | 394.6 K to 386.6 K (-2.01 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.46 | 4,500 | 155,070 | 394,550 | 399.1 K to 394.6 K (-1.13 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.44 | 3,659 | 126,016 | 399,050 | 402.7 K to 399.1 K (-0.91 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.42 | 3,000 | 103,260 | 402,709 | 405.7 K to 402.7 K (-0.74 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.41 | 2,500 | 86,025 | 405,709 | 408.2 K to 405.7 K (-0.61 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.40 | 2,400 | 82,560 | 408,209 | 410.6 K to 408.2 K (-0.58 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.43 | 2,000 | 68,860 | 410,609 | 412.6 K to 410.6 K (-0.48 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.49 | 1,200 | 41,388 | 412,609 | 413.8 K to 412.6 K (-0.29 %) |
Mar 06 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Sell | S | 34.45 | 400 | 13,780 | 413,809 | 414.2 K to 413.8 K (-0.10 %) |
Feb 27 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 34.59 | 120,805 | 4,178,645 | 120,805 | |
Feb 27 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | A | 34.59 | 144,928 | 5,013,060 | 144,928 | |
Feb 27 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Option Exercise | M | 17.69 | 146,396 | 2,589,745 | 0 | |
Feb 27 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 33.47 | 57,692 | 1,930,951 | 414,209 | 471.9 K to 414.2 K (-12.23 %) |
Feb 27 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 34.66 | 44,915 | 1,556,754 | 471,901 | 516.8 K to 471.9 K (-8.69 %) |
Feb 27 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Payment of Exercise | F | 34.66 | 8,497 | 294,506 | 516,816 | 525.3 K to 516.8 K (-1.62 %) |
Feb 27 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Grant | A | 0.00 | 23,006 | 0 | 525,313 | 502.3 K to 525.3 K (+4.58 %) |
Feb 27 2015 | PFE | PFIZER INC | Dolsten Mikael | President R&D | Buy | M | 17.69 | 146,396 | 2,589,745 | 502,307 | 355.9 K to 502.3 K (+41.13 %) |
Oct 19 2009 | WYE | WYETH | Dolsten Mikael | Sr. VP & Pres., Wye ... | Option Exercise | D | 43.08 | 52,000 | 2,240,160 | 0 | |
Jun 18 2008 | WYE | WYETH | Dolsten Mikael | Sr. VP & Pres., Wye ... | Option Exercise | A | 43.08 | 52,000 | 2,240,160 | 52,000 |
Page: 1